<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2007-7459</journal-id>
<journal-title><![CDATA[Horizonte sanitario]]></journal-title>
<abbrev-journal-title><![CDATA[Horiz. sanitario]]></abbrev-journal-title>
<issn>2007-7459</issn>
<publisher>
<publisher-name><![CDATA[Universidad Juárez Autónoma de Tabasco, División Académica de Ciencias de la Salud]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2007-74592017000200093</article-id>
<article-id pub-id-type="doi">10.19136/hs.v16i2.1469</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Papel de la superfamilia ABC en la resistencia farmacológica]]></article-title>
<article-title xml:lang="en"><![CDATA[Role of the superfamily of ABC transports in pharmacological resistance]]></article-title>
<article-title xml:lang="pt"><![CDATA[Papel da superfamília ABC na resistência a drogas]]></article-title>
<article-title xml:lang="fr"><![CDATA[Rôle de la superfamille ABC dans la résistance pharmacologique]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Morales-Pérez]]></surname>
<given-names><![CDATA[Mayasil]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[García-Milian]]></surname>
<given-names><![CDATA[Ana Julia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto de Ciencias Básicas y Preclínicas &#8220;Victoria de Girón&#8221; Departamento Farmacología ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Escuela Nacional de Salud Pública  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>08</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>08</month>
<year>2017</year>
</pub-date>
<volume>16</volume>
<numero>2</numero>
<fpage>93</fpage>
<lpage>101</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2007-74592017000200093&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2007-74592017000200093&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2007-74592017000200093&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Objetivo: Actualizar los conocimientos acerca de los transportadores de la superfamilia ABC vinculados con la resistencia farmacológica.  Materiales y métodos: Se realizó un estudio donde se aplicó el método cualitativo, mediante una revisión bibliográfica y documental sobre el tema en fuentes de datos digitales. Se usaron los descriptores DeCs-MeSH: transportadores ABC, superfamilia ABC, resistencia farmacológica, ATP binding- cassette. Se revisaron artículos publicados sobre el tema, a través de los buscadores habituales (Google, PubMed, Cochrane, Future Medicine, Scielo, entre otros), teniendo en cuenta la calidad y la actualidad de ellos.  Resultados: Se destaca la importancia clínica de estos transportadores que se relacionan con la aterosclerosis, enfermedades hepáticas, enfermedad de Alzheimer, entre otras. Esto los convierte en dianas atractivas para el diseño de nuevos medicamentos; pero al mismo tiempo, pueden expulsarlos de la célula, haciéndola resistente como a los antitumorales, antimicrobianos y antivirales.  Conclusiones: Los transportadores ABC tienen una función central en los efectos adversos que diferentes sustancias, entre ellas los fármacos, tienen sobre la célula. Además, el polimorfismo genético en esta superfamilia se asocia con alteraciones farmacocinéticas que pueden desencadenar resistencia farmacológica; el impacto de estas modificaciones es el centro de recientes investigaciones que las sitúan como posible blanco terapéutico.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Objective: To update the knowledge about the ABC transporters superfamily linked to drug resistance.  Materials and methods: A qualitative study where the method was applied, using a bibliographical and documentary review on the subject of digital data sources was conducted. ABC transporters, ABC superfamily, and drug resistance, binding- ATP cassette: the DECS-MeSH descriptors were using published articles on the subject through the usual search engines (Google, PubMed, Cochrane, Future Medicine, Scielo, among others), counting on the quality and timeliness of them were review.  Results: The clinical significance of these transporters is stress as they relate to atherosclerosis, liver disease, Alzheimer's disease, among other conditions. This makes them attractive targets for new drug design; but at the same time, they can expel the cell making it resistant as antitumor, antimicrobial and antiviral.  Conclusions: ABC transporters have central role in the adverse effects of different substances, including drugs, have on the cell. In addition, the genetic polymorphism in this superfamily is associated with pharmacokinetic changes that can trigger drug resistance; the impact of these changes is the focus of recent research that place them as a possible therapeutic target.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo  Objectivo: Atualizar o conhecimento sobre os transportadores de superfamilia ABC ligada a resistência a drogas.  Materiais e métodos: Foi realizado um estudo qualitativo, através de uma revisão da literatura e documental sobre o tema em fontes de dados digitais. Foram utilizados os descritores DeCs-MeSH: transportadores ABC, superfamilia ABC, resistência farmacológica, ATP binding- cassette. Foram pesquisados artigos sobre o tema, através dos motores de busca (Google, PubMed, Cochrane, Future Medicine, Scielo, entre outros), tendo em conta a qualidade e a sua atualidade.  Resultados: Destacou-se a importãncia clínica destes transportadores que se relacionam com a aterosclerose, doen9as hepáticas, de Alzheimer, entre outras. Isso os torna alvos atraentes para o design de novos fármacos, mas ao mesmo tempo, os fármacos podem ser expulsos da célula, tornando-a resistente aos antitumorais, antimicrobianos e antivirais.  Conclusões: Os transportadores ABC têm uma função central nos efeitos adversos que diferentes substãncias, tais como os fármacos, possuem sobre a célula. Além disso, o polimorfismo genético desta superfamilia está associado as alterações farmacocinéticas que podem desencadear a resistência aos medicamentos; o impacto dessas mudanças é o centro de pesquisas recentes que os coloca como um possível alvo terapéutico.]]></p></abstract>
<abstract abstract-type="short" xml:lang="fr"><p><![CDATA[Résumé  Objectif: Actualiser les connaissances sur les transporteurs de la superfamille ABC liés a la résistance pharmacologique.  Matériaux et méthodes: Une étude qualitative a été réalisée au moyen d&#8217;une recherche bibliographique et documentaire dans différentes sources de données numériques avec les moteurs de recherche habituels (Google, PubMed, Cochrane, Medicine Future, Scielo, entre autres). Les descripteurs DeCs-MeSH utilisés ont été: transporteurs ABC, superfamille ABC, résistance pharmacologique, ATP binding- cassette. Un certain nombre d&#8217;articles relatifs au sujet ont été sélectionnés en fonction de leur qualité et de leur actualité.  Résultats: Les résultats mettent en avant l&#8217;importance clinique de ces transporteurs du fait de leur relation avec l'athérosclérose, certaines maladies hépatiques, la maladie d'Alzheimer, et d&#8217;autres affections. Cela en fait des cibles attrayantes pour la conception de nouveaux médicaments; mais en meme temps, ils peuvent expulser des médicaments de la cellule et la rendre résistante aux antitumoraux, antimicrobiens et antiviraux, par exemple.  Conclusions: Les transporteurs ABC jouent un role central dans les conséquences néfastes de différentes substances, y compris les médicaments, sur la cellule. En outre, le polymorphisme génétique dans cette superfamille est associé a des modifications pharmacocinétiques qui peuvent déclencher une résistance aux médicaments; l'impact de ces modifications est l'objet de recherches récentes qui les placent comme cible thérapeutique possible.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Transportadores ABC]]></kwd>
<kwd lng="es"><![CDATA[Superfamilia ABC]]></kwd>
<kwd lng="es"><![CDATA[Resistencia farmacológica]]></kwd>
<kwd lng="es"><![CDATA[ATP binding- cassette]]></kwd>
<kwd lng="en"><![CDATA[ABC transporters]]></kwd>
<kwd lng="en"><![CDATA[ABC superfamily]]></kwd>
<kwd lng="en"><![CDATA[Drug resistance]]></kwd>
<kwd lng="en"><![CDATA[ATP binding- cassette]]></kwd>
<kwd lng="pt"><![CDATA[Transportadores ABC]]></kwd>
<kwd lng="pt"><![CDATA[Superfamilia ABC]]></kwd>
<kwd lng="pt"><![CDATA[Resistencia farmacológica]]></kwd>
<kwd lng="pt"><![CDATA[ATP binding- cassette]]></kwd>
<kwd lng="fr"><![CDATA[Transporteurs ABC]]></kwd>
<kwd lng="fr"><![CDATA[Superfamille ABC]]></kwd>
<kwd lng="fr"><![CDATA[Résistance aux médicaments]]></kwd>
<kwd lng="fr"><![CDATA[ATP binding- cassette]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cardellá]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Hernández]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[Bioquímica médica]]></source>
<year>2014</year>
<volume>2</volume>
<edition>2</edition>
<page-range>377- 400</page-range><publisher-loc><![CDATA[La Habana ]]></publisher-loc>
<publisher-name><![CDATA[Ecimed]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Becker]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Kleinsmith]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Hardin]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[El mundo de la célula]]></source>
<year>2007</year>
<edition>6</edition>
<page-range>211- 242</page-range><publisher-loc><![CDATA[Madrid ]]></publisher-loc>
<publisher-name><![CDATA[Pearson Educación, S.A]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cooper]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Hausmn]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[La célula]]></source>
<year>2011</year>
<edition>5</edition>
<page-range>529- 551</page-range><publisher-loc><![CDATA[Madrid ]]></publisher-loc>
<publisher-name><![CDATA[Marbán]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lehninger]]></surname>
</name>
</person-group>
<source><![CDATA[Principios de Bioquímica]]></source>
<year>2014</year>
<edition>6</edition>
<page-range>390- 402</page-range><publisher-loc><![CDATA[Barcelona ]]></publisher-loc>
<publisher-name><![CDATA[Omega]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Giacomini]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Sugiyama]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Transportadores de membrana y respuesta a los fármacos]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Gilman]]></surname>
<given-names><![CDATA[Goodman]]></given-names>
</name>
</person-group>
<source><![CDATA[Las bases farmacológicas de la terapéutica]]></source>
<year>2011</year>
<edition>12</edition>
<page-range>89- 120</page-range><publisher-loc><![CDATA[México D.F ]]></publisher-loc>
<publisher-name><![CDATA[McGraw Hill]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Villar]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[del Arco]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Flórez]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metabolismo de los fármacos]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Flórez]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[farmacología humana]]></source>
<year>2014</year>
<edition>6</edition>
<page-range>72- 82</page-range><publisher-loc><![CDATA[Barcelona ]]></publisher-loc>
<publisher-name><![CDATA[Elsevier]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Pharmacogenomic importance of ABCG2.]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cusatis]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Sparreboom]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Pharmacogenomics]]></source>
<year>2008</year>
<volume>9</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1005-9</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[ABC multidrug transporters: structure, function and role in chemoresistance.]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sharon]]></surname>
<given-names><![CDATA[FJ]]></given-names>
</name>
</person-group>
<source><![CDATA[Pharmacogenomics]]></source>
<year>2008</year>
<volume>91</volume>
<page-range>105-27</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hoos]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Development of inmuno-oncology drugs]]></source>
<year>2016</year>
<publisher-name><![CDATA[Macmillan Publisher]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Herrera]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[Farmacovigilancia, hacia una mayor seguridad en el uso de los medicamentos]]></source>
<year>2012</year>
<edition>1</edition>
<page-range>143- 80</page-range><publisher-loc><![CDATA[Córdoba ]]></publisher-loc>
<publisher-name><![CDATA[Raquel Herrera Comoglio ediciones]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Mechanisms to target cancer therapies.]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lackner]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Wilson]]></surname>
<given-names><![CDATA[TR]]></given-names>
</name>
<name>
<surname><![CDATA[Settleman]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Future Oncol]]></source>
<year>2012</year>
<volume>8</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>999-1014</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="book">
<source><![CDATA[The intemational transporter consortium. Membrane transporters in drugs development]]></source>
<year>2010</year>
<volume>9</volume>
<publisher-name><![CDATA[Macmillan Publisher Reviews]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Association of ATP- binding cassette transporter variants with the risk of Alzheimer's disease.]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cascorbi]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Ch]]></surname>
<given-names><![CDATA[Fluh]]></given-names>
</name>
<name>
<surname><![CDATA[Remmler]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Haenish]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Faltraco]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Grumbt]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Pharmacogenomics]]></source>
<year>2013</year>
<volume>14</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>485-94</page-range></nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[ABCA1, apoE and apoA-I as potential therapeutic targets for treating Alzheimer's disease]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Namjoshi]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Stukas]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[ChL]]></surname>
<given-names><![CDATA[Wellington]]></given-names>
</name>
</person-group>
<source><![CDATA[Neurodegen Diseas Managmt]]></source>
<year>2011</year>
<volume>1</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>245- 59</page-range></nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Hepatobiliary transport in health and disease.]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chan]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Vandeberg]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Clin Lipid]]></source>
<year>2012</year>
<volume>7</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>189- 202</page-range></nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Role of the ABC transporters ABCA1 and ABCG1 in foam cell formation and aterosclerosis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Meurs]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Out]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Van Berkel]]></surname>
<given-names><![CDATA[TJC]]></given-names>
</name>
<name>
<surname><![CDATA[van Eck]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Future Lipid]]></source>
<year>2008</year>
<volume>3</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>675-87</page-range></nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[SLC transporters as terapeutic targets: emerging opportunities]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lin]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Wah]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[RB]]></given-names>
</name>
<name>
<surname><![CDATA[Giacomini]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Nat Rev Drug Discov]]></source>
<year>2015</year>
<volume>14</volume>
</nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fort]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<source><![CDATA[Principio básicos de la farmacología oncológica. Resistencia a la qimioterapia]]></source>
<year>2010</year>
<publisher-name><![CDATA[Institute Catalá d'Oncologia, departament de salut]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nigam]]></surname>
<given-names><![CDATA[SK]]></given-names>
</name>
</person-group>
<source><![CDATA[What do drug transporters really do?]]></source>
<year>2015</year>
<volume>14</volume>
<publisher-name><![CDATA[Macmillan Publisher Reviews]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The expression profile of ATP- binding cassette transporter genes in breast carcinoma]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hlavac]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Brynychova]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Vaclavikova]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Ehrlichova]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Vrana]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Pecha]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<source><![CDATA[Pharmacogenomics]]></source>
<year>2013</year>
<volume>14</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>515-29</page-range></nlm-citation>
</ref>
<ref id="B21">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Multiple drug resistance mechanisms in cancer]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Baguley]]></surname>
<given-names><![CDATA[BC]]></given-names>
</name>
</person-group>
<source><![CDATA[Mol. Biotechnol]]></source>
<year>2010</year>
<volume>46</volume>
<page-range>308- 16</page-range></nlm-citation>
</ref>
<ref id="B22">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Robins]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Foul]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[The expression profile of ABC transporter genes in post- treatment breast carcinomas]]></source>
<year>2011</year>
</nlm-citation>
</ref>
<ref id="B23">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Metabolism and transport of tamoxifen relation to its effectiveness: new perspectives on an ongoing contro versial]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cronin- Fenton]]></surname>
<given-names><![CDATA[DP]]></given-names>
</name>
<name>
<surname><![CDATA[Damkier]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Lash]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<source><![CDATA[Future Oncol]]></source>
<year>2014</year>
<volume>10</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>107-22</page-range></nlm-citation>
</ref>
<ref id="B24">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[ABCB1 gene polymorphisms are associated with adverse reactions in fluoropyrimmide treatment colorectal cáncer patients]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gonzalez-Haba]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[García]]></surname>
<given-names><![CDATA[MI]]></given-names>
</name>
<name>
<surname><![CDATA[Cortejoso]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Loez- Lillo]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Barrueco]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[García-Alfonso]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<source><![CDATA[Pharmacogenomics]]></source>
<year>2010</year>
<volume>11</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>11715-23</page-range></nlm-citation>
</ref>
<ref id="B25">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Lenght variants of the ABCB1 3'-UTR and loss of miRNA binding site posible nonsequences in regulation and pharmacotherapy instance]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bruhn]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Drerup]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Kaehler]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Haenish]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Rhoder]]></surname>
<given-names><![CDATA[CH]]></given-names>
</name>
<name>
<surname><![CDATA[Cascorbi]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<source><![CDATA[Pharmacogenomics]]></source>
<year>2016</year>
<volume>17</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>327- 340</page-range></nlm-citation>
</ref>
<ref id="B26">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[BCRP/ ABCG2 confers anticancer drug resistance without covalent dimerization.]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shigeta]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Katayama]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Mitsuhashi]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Cancer Sci]]></source>
<year>2010</year>
<volume>101</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1813- 21</page-range></nlm-citation>
</ref>
<ref id="B27">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Cancer stem cells and drug resistance: the potencial of nanomedicine]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vinagradov]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Wei]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
</person-group>
<source><![CDATA[Nanomedicine]]></source>
<year>2012</year>
<volume>7</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>597-615</page-range></nlm-citation>
</ref>
<ref id="B28">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Role of nanomedicine in reversing drug resistance mediated by ATP binding cassette transporters and P- glycoprotein in melanoma]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kanwar]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Singh]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Kanwar]]></surname>
<given-names><![CDATA[RK]]></given-names>
</name>
</person-group>
<source><![CDATA[Nanomedicine]]></source>
<year>2011</year>
<volume>6</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>701- 714</page-range></nlm-citation>
</ref>
<ref id="B29">
<nlm-citation citation-type="book">
<article-title xml:lang=""><![CDATA[R. Principios generales del tratamiento antimicrobiano]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Goodman]]></surname>
</name>
<name>
<surname><![CDATA[Gilman]]></surname>
</name>
</person-group>
<source><![CDATA[Las bases farmacológicas de la terapéutica]]></source>
<year>2011</year>
<edition>12</edition>
<page-range>1365- 82</page-range><publisher-loc><![CDATA[México D.F ]]></publisher-loc>
<publisher-name><![CDATA[McGraw Hill]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B30">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gumbo]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Quimioterapia de la tuberculosis, la enfermedad causada por mycobacterium avium y la lepra]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Goodman]]></surname>
</name>
<name>
<surname><![CDATA[Gilman]]></surname>
</name>
</person-group>
<source><![CDATA[Las bases farmacológicas de la terapéutica]]></source>
<year>2011</year>
<edition>12</edition>
<page-range>1549-71</page-range><publisher-loc><![CDATA[México D.F ]]></publisher-loc>
<publisher-name><![CDATA[McGraw Hill]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B31">
<nlm-citation citation-type="">
<article-title xml:lang=""><![CDATA[Resistencia a los fármacos antirretrovirales]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carmona]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Actas de 2° Seminario de atención farmacéutica]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B32">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ch]]></surname>
<given-names><![CDATA[Flexner]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antirretrovirales y tratamiento de la infección por VIH]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Gilman]]></surname>
<given-names><![CDATA[Goodman &]]></given-names>
</name>
</person-group>
<source><![CDATA[Las bases farmacológicas de la terapéutica]]></source>
<year>2011</year>
<edition>12</edition>
<page-range>1623- 65</page-range><publisher-loc><![CDATA[México D.F ]]></publisher-loc>
<publisher-name><![CDATA[McGraw Hill]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B33">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[2011 update of drug resistance mutations in HIV]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Johnson]]></surname>
<given-names><![CDATA[VA]]></given-names>
</name>
<name>
<surname><![CDATA[Calvez]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Gunthard]]></surname>
<given-names><![CDATA[HF]]></given-names>
</name>
<name>
<surname><![CDATA[Paredes]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Pillay]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Shafer]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[Top Antivir Med]]></source>
<year>2011</year>
<volume>19</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>156- 64</page-range></nlm-citation>
</ref>
<ref id="B34">
<nlm-citation citation-type="book">
<collab>Programa VIH/ SIDA</collab>
<source><![CDATA[Actualización pragmática: Uso de antirretrovirales para tratar las embarazadas y prevenir la infección por el VIH en los lactantes]]></source>
<year>2012</year>
<publisher-name><![CDATA[OMS]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B35">
<nlm-citation citation-type="book">
<collab>Programa VIH/ SIDA</collab>
<source><![CDATA[Marco de acción del tratamiento 2.0: impulsando la próxima generación del tratamiento, la atención y el apoyo]]></source>
<year>2011</year>
<publisher-name><![CDATA[OMS]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B36">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Resistencia a antirretrovirales: bases moleculares e implicaciones farmacológicas]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vanegas]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Acevedo]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Díaz]]></surname>
<given-names><![CDATA[FJ]]></given-names>
</name>
<name>
<surname><![CDATA[Velilla]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<source><![CDATA[Rev CES Med]]></source>
<year>2014</year>
<volume>28</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>91- 106</page-range></nlm-citation>
</ref>
<ref id="B37">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Novel antiseizure drug mechanisms]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Andrade]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Carlen]]></surname>
<given-names><![CDATA[PL]]></given-names>
</name>
</person-group>
<source><![CDATA[Future neurology]]></source>
<year>2007</year>
<volume>2</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>273- 86</page-range></nlm-citation>
</ref>
<ref id="B38">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Complex haplotypic effects of the ABCB1 gene on the epilepsy response]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ch]]></surname>
<given-names><![CDATA[Hung]]></given-names>
</name>
<name>
<surname><![CDATA[Tai]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Ch]]></surname>
<given-names><![CDATA[Lin]]></given-names>
</name>
<name>
<surname><![CDATA[Lin]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Liou]]></surname>
<given-names><![CDATA[HH]]></given-names>
</name>
</person-group>
<source><![CDATA[Pharmacogenomics]]></source>
<year>2005</year>
<volume>6</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>411- 17</page-range></nlm-citation>
</ref>
<ref id="B39">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[ABCB1 polymorphisms influence response to antiepilectic drugs in Japanese epilepsy patients]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Seo]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Ishitsu]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Ueda]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Nakada]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Yurube]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<source><![CDATA[Pharmacogenomics]]></source>
<year>2006</year>
<volume>7</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>551- 61</page-range></nlm-citation>
</ref>
<ref id="B40">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Association of SNC1A, SNC 2 A and ABCB2 gene polymorphisms with the response to antipilectic drugs in Chinese Hun patients with epilepsy]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ch-L]]></surname>
<given-names><![CDATA[Ma]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[X-Y]]></given-names>
</name>
<name>
<surname><![CDATA[Zheng]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[Z-Y]]></given-names>
</name>
<name>
<surname><![CDATA[Hong]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
</person-group>
<source><![CDATA[Pharmacogenomics]]></source>
<year>2014</year>
<volume>15</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1323- 36</page-range></nlm-citation>
</ref>
<ref id="B41">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Lack of association between ABCC2 gene variants and treatment response in epilepsy]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hilger]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Reintaler]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Estogmann]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Ch]]></surname>
<given-names><![CDATA[Hotzy]]></given-names>
</name>
<name>
<surname><![CDATA[Pataraia]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<source><![CDATA[Pharmacogenomics]]></source>
<year>2012</year>
<volume>13</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>185-90</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
